outbreak
sever
acut
respiratori
syndrom
coronaviru
sarscov
might
reemerg
identifi
antivir
compound
key
import
previous
show
cellular
factor
convert
enzym
tace
activ
spike
protein
sarscov
sarss
protein
posit
involv
viral
entri
impli
tace
possibl
target
develop
antivir
compound
demonstr
possibl
test
effect
tace
inhibitor
viral
entri
vitro
vivo
data
reveal
tace
inhibitor
attenu
entri
pseudotyp
viru
express
sarss
protein
lentivir
vector
backbon
infecti
sarscov
block
sarss
proteininduc
shed
angiotensinconvert
enzym
receptor
sarscov
product
lung
tissu
sinc
downregul
sarss
protein
propos
etiolog
event
sever
clinic
manifest
data
suggest
tace
antagonist
block
sarscov
infect
also
attenu
sever
clinic
outcom
outbreak
sever
acut
respiratori
syndrom
coronaviru
sarscov
infect
spread
quickli
south
china
countri
worldwid
http
individu
infect
mortal
rate
ksiazek
et
al
angiotensinconvert
enzym
identifi
cellular
receptor
sarscov
li
et
al
bind
sarscov
spike
protein
sarss
protein
clearli
shown
requir
initi
step
viral
entri
li
et
al
wong
et
al
base
analysi
molecular
interact
sarss
protein
subsequ
process
viral
entri
kuhn
et
al
sever
target
avail
develop
antivir
compound
liu
et
al
simmon
et
al
sui
et
al
sinc
recurr
outbreak
sarscov
reemerg
develop
compound
prevent
sarscov
critic
import
previous
found
convert
enzym
tace
requir
viral
entri
haga
et
al
tace
origin
identifi
metalloproteas
requir
process
membran
form
releas
solubl
factor
black
et
al
involv
cleavag
releas
ectodomain
lambert
et
al
tacedepend
shed
complet
depend
bind
sarss
protein
haga
et
al
addit
sirna
experi
demonstr
tace
requir
effici
viral
entri
haga
et
al
impli
tace
might
target
antivir
compound
sarscov
sinc
downregul
caus
sarss
protein
postul
correl
sever
respiratori
failur
kuba
et
al
tace
inhibitor
might
also
attenu
tissu
damag
caus
viral
infect
therefor
analyz
antivir
activ
hydroxamatebas
tace
inhibitor
mohler
et
al
black
et
al
first
studi
effect
tace
inhibitor
shed
bind
sarss
protein
western
blot
analysi
detect
shed
form
ectodomain
kda
size
cultur
supernat
treatment
sarss
protein
fig
lane
cell
pretreat
nm
fig
lane
nm
lane
h
sarssinduc
shed
attenu
significantli
sinc
solubl
form
releas
cell
haga
et
al
ad
h
protein
present
cultur
supernat
recov
coprecipit
ovalbumin
ova
trichloroacet
acid
subject
western
blot
analysi
previous
describ
haga
et
al
lane
control
without
addit
sarss
protein
lane
salin
sarss
protein
lane
sarss
protein
lane
sarss
protein
cultur
supernat
collect
h
lane
h
lane
b
c
inhibit
releas
activ
cultur
supernat
activ
measur
supernat
vero
cell
cultur
without
nm
horizont
axi
show
incub
time
fluoresc
substrat
mcayvadapkdnpoh
amino
acid
depict
singl
letter
r
system
minneapoli
mn
b
rel
rate
inhibit
calcul
base
data
shown
b
min
c
e
inhibit
releas
activ
cultur
supernat
experi
carri
procedur
describ
b
c
use
concentr
nm
membran
catalyt
activ
tipni
et
al
measur
carboxymonopeptidas
activ
cultur
supernat
although
activ
increas
sarss
protein
treatment
fig
pretreat
decreas
activ
p
fig
c
p
fig
control
respect
show
sarss
protein
induc
tace
activ
measur
tace
activ
cellular
extract
fluoresc
intens
cleav
substrat
monitor
extract
cell
treat
without
min
differ
detect
tace
activ
control
sampl
sampl
treat
b
block
tace
activ
tace
activ
detect
h
ad
sarss
protein
block
complet
pretreat
p
timecours
analysi
tace
activ
reveal
addit
sarss
protein
gradual
increas
tace
activ
cellular
extract
fig
six
hour
ad
sarss
protein
tace
activ
increas
significantli
p
fig
howev
addit
block
increas
tace
activ
upregul
sarss
protein
fig
b
p
data
indic
shed
ectodomain
induc
sarss
protein
coupl
tace
activ
previous
propos
haga
et
al
next
examin
effect
tace
inhibitor
viral
infect
first
use
pseudotyp
viru
express
sarss
protein
core
structur
lentivir
vector
sarss
viru
measur
intracellular
gag
protein
test
cell
previou
observ
result
obtain
measur
consist
measur
use
realtim
rtpcr
sarscov
mrna
haga
et
al
plasmid
express
introduc
cell
cell
extract
prepar
h
viral
infect
fig
treatment
two
tace
inhibitor
nm
nm
h
infect
sarss
viru
attenu
viral
entri
significantli
p
p
shown
fig
b
respect
next
examin
inhibitori
effect
viral
entri
infecti
frankfurt
strain
sarscov
detect
mark
reduct
viral
infect
compound
fig
vivo
effect
tace
inhibitor
viral
entri
examin
use
sarss
pseudotyp
viru
h
intratrach
administr
l
viral
solut
gml
lung
tissu
reflux
ml
phosphatebas
buffer
gml
trypsin
excis
measur
intracellular
protein
lung
tissu
extract
use
homogen
subject
enzymelink
immunosorb
assay
elisa
shown
fig
pretreat
h
viral
challeng
significantli
decreas
intracellular
left
panel
right
panel
respect
moreov
treatment
also
reduc
amount
solubl
content
gener
viral
infect
p
fig
next
test
antivir
effect
infecti
sarscov
challeng
adult
femal
balbc
mice
anim
experi
approv
anim
care
use
committe
nation
institut
infecti
diseas
tokyo
japan
work
infecti
sarscov
perform
biosafeti
level
condit
experiment
protocol
shown
fig
left
panel
experi
use
instead
water
solubl
see
also
legend
fig
group
administ
twice
viral
challeng
group
administ
total
three
time
addit
pretreat
viral
inocul
control
salin
administ
condit
group
day
viral
challeng
lung
lavag
perform
viral
titer
measur
shown
fig
right
panel
tripl
administr
significantli
reduc
viral
titer
p
show
evid
tace
target
candid
antisarscov
agent
data
reveal
nm
level
tapi
reproduc
inhibit
viral
entri
vitro
addit
partial
block
viral
infect
sarscov
vivo
previous
report
tace
cellular
factor
involv
effici
viru
entri
haga
et
al
experi
use
cell
line
embryon
fibroblast
taceknockout
mice
reveal
infect
sarss
viru
strictli
depend
exogen
transduc
tace
cdna
addit
tace
sirna
attenu
entri
sarss
pseudotyp
viru
infecti
sarscov
current
data
consist
previou
report
although
effect
suppress
viral
entri
sarss
pseudotyp
viru
fig
right
panel
infecti
sarscov
suppress
sarss
proteindepend
viral
entri
plasmid
dna
encod
introduc
cell
cell
infect
viru
cell
treat
b
h
infect
sarss
pseudotyp
lentiviru
invitrogen
carlsbad
ca
h
intracellular
measur
use
retrotek
elisa
kit
zeptometrix
buffalo
ny
accord
manufactur
instruct
c
block
entri
infecti
sarscov
viral
infect
effici
measur
use
realtim
rtpcr
viral
mrna
describ
haga
et
al
test
sampl
harvest
analyz
h
infect
sarscov
data
normal
use
ribosom
rna
experi
use
water
solubl
wherea
water
insolubl
requir
control
sampl
treat
dimethylsulfoxid
dmso
solvent
fig
vitro
inhibitori
effect
drastic
vivo
fig
one
possibl
explan
tace
might
singl
target
complet
suppress
viral
infect
work
done
independ
research
group
shown
sarscov
use
dcsign
dendrit
cellspecif
grab
nonintegrin
l
liverlymph
nodespecif
sign
dclsign
addit
cellular
receptor
han
et
al
jeffer
et
al
shih
et
al
propos
mode
viral
entri
via
molecul
differ
han
et
al
observ
lend
support
notion
combin
administr
antagonist
tace
dclsign
would
lead
remark
inhibit
viral
infect
sarscov
anoth
possibl
complet
blockag
viru
entri
might
requir
effici
suppress
viral
product
seem
viral
replic
sarscov
crucial
determin
whole
test
effect
l
compound
dissolv
dmso
amount
dilut
dmso
administ
intratrach
h
viral
challeng
n
per
group
respect
addit
control
effect
viral
entri
vsvg
pseudotyp
lentiviru
also
examin
h
lung
tissu
first
reflux
ml
phosphatebas
buffer
ml
phosphatebas
buffer
contain
gml
collagenas
ml
phosphatebuff
salin
contain
gml
trypsin
extract
extract
measur
use
elisa
kit
right
panel
test
l
compound
water
volum
distil
water
administ
method
right
panel
n
per
group
measur
intracellular
similar
procedur
b
effect
product
viral
infect
water
control
lung
tissu
prepar
without
reflux
use
collagenas
trypsin
subject
analysi
elisa
n
per
group
c
effect
viral
infect
infecti
sarscov
left
panel
protocol
sarscov
inocul
treatment
experi
use
water
solubl
although
seem
effect
better
vivo
experi
necessari
includ
addit
control
group
treat
dmso
solvent
sevenweekold
femal
balbc
mice
pretreat
l
salin
via
intranas
inject
anesthesia
soon
afterward
mice
infect
l
mousepassag
frankfurt
isol
sarscov
nagata
et
al
via
intranas
inocul
three
hour
day
viru
inocul
anim
treat
l
salin
via
intranas
inject
anesthesia
right
panel
viru
titer
lung
lavag
fluid
day
inocul
salin
n
per
group
balbc
mice
viru
titer
lung
lavag
fluid
inocul
detect
limit
fluid
amount
viru
produc
vivo
even
singl
particl
viru
infect
vigor
replic
vivo
overcom
subtl
inhibitori
effect
compound
viral
entri
implic
import
develop
potent
antagonist
recent
lu
et
al
identifi
specif
inhibitor
tace
ic
nm
porcin
tace
plausibl
specul
compound
would
suppress
sarscov
infect
effect
current
use
tace
antagonist
ic
inhibit
viral
entri
effici
nm
data
reveal
antitac
compound
also
attenu
product
viral
infect
suggest
compound
might
effect
protect
patient
clinic
manifest
diseas
tace
member
adam
disintegrin
metalloproteas
famili
involv
varieti
biolog
function
target
drug
develop
variou
diseas
seal
courtneidg
